Tafamidis Meglumine Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

In November 2011, the European Commission approved tafamidis meglumine (Fx-1006A, PF-06291826) for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy. Tafamidis stabilizes both the wild type and mutant forms of TTR tetramer and prevents tetramer dissociation by noncooperatively binding to the two thyroxine binding sites. Tafamidis is the first approved medicine for TTR-FAP. The Kd values for tafamidis for the two thyroxine binding sites on TTR, as determined by isothermal titration calorimetry, were 3 nM and 278 nM, respectively. In another in vitro study using wild type TTR, V30M mutant TTR, and V122I mutant TTR, it was shown that tafamidis inhibited fibril formation in a concentration-dependent manner reaching EC₅₀ at a tafamidis:TTR stoichiometry of <1 (EC₅₀ was in the range of 2.7–3.2 μM, corresponding to a tafamidis:TTR stoichiometry range of 0.75–0.9). Tafamidis has been synthesized by coupling 4-amino-3- hydroxybenzoic acid with 3,5-dichlorobenzoyl chloride followed by dehydration using p-toluenesulfonic acid.

Verwenden

Tafamidis Meglumine is used as a potential therapeutics for COVID-19 and related viral infections

Clinical Use

Tafamidis meglumine is a transthyretin amyloid inhibitor that was approved for the treatment of transthyretin amyloid polyneuropathy (ATTR-PN) and transthyretin familial amyloid polyneropathy (TTR-FAP). These diseases represent a rare autosomal neurodegenerative disorder characterized by autonomic, sensory and motor impairment which are typically fatal. Tafamidis was discovered at The Scripps Research Institute and developed by Pfizer.

Tafamidis Meglumine Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Tafamidis Meglumine Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Shijiazhuang Dingmin Pharmaceutical Sciences Co., Ltd.	+86-0311-67591193 +8615933619867	sales@dingminpharma.com	China	252	58
Hebei Mujin Biotechnology Co.,Ltd	+86 13288715578 +8613288715578	sales@hbmojin.com	China	12830	58
Hebei Weibang Biotechnology Co., Ltd	+8617732866630	bess@weibangbio.com	China	18148	58
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	32161	58
Chemia Biotechnology（Shanghai） Co., Ltd	+8613816753574	info@chemia-pharm.com	CHINA	311	58
Guangzhou TongYi biochemistry technology Co.,LTD	+8613073028829	mack@tongyon.com	China	2994	58
InvivoChem	+1-708-310-1919 +1-13798911105	sales@invivochem.cn	United States	6391	58
Hefei TNJ Chemical Industry Co.,Ltd.	+86-0551-65418684 +8618949823763	sales@tnjchem.com	China	25356	58
Jiangxi Huihe Chemical Co., Ltd.	+86-19189228086 +8618858568638	wuzhouding@huihecrop.com	China	886	58
Nanjing Doge Biomedical Technology Co., Ltd	+86-25-58227606 +86-15305155328	sales@dogechemical.com	China	4128	58

---

• Tafamidis Meglumine
• 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine
• cas 594839-88-0
• PF06291826
• PF-06291826
• TAFAMIDIS;CAS 594839-88-0;PF-06291826;PF06291826
• Tafamidis meglumine (Fx1006, PF06291826)
• tafamidis meglumine,Inhibitor,Tafamidis,inhibit
• Tafamidis-meglumine API
• afamidis Meglumine
• He prescribed metoclopramide
• (2R,3R,4R,5S)-6-(Methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylate
• Meglumine clobenzolate
• 951395-08-7
• C21H24Cl2N2O8
• C7H17NO5C14H7Cl2NO3
• API